WELCOME TO THE NEWSROOM

WATCH OUR LATEST VIDEO

Category: Financing

NeuMoDx™ Announces Completion of Series B Financing Funds Product Development for High Throughput Molecular Diagnostic Platform Ann Arbor, Michigan (March 26, 2014) – NeuMoDx™ Molecular, Inc., a privately held diagnostics company developing a new platform for high throughput, low cost molecular testing, today announced completion of its Series B financing. Pfizer Ventures led the $21 million...

IMPORTANT ANNOUNCEMENT

We are excited to announce that QIAGEN has acquired all shares of NeuMoDx Molecular, Inc. The addition of NeuMoDx’s medium- and high-throughput molecular systems further expands QIAGEN’s portfolio of molecular diagnostics instruments, bolstering our leadership in automated molecular testing. We are proud to welcome NeuMoDx to our family of PCR solutions that make improvements in life possible.

To learn more, click here.